© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.
Melbourne, Australia -- Novartis Animal Health signed an agreement March 31 with Australian pharmaceutical company Phosphagenics Ltd. to develop a transdermal insulin delivery system for pets.
Melbourne, Australia
-- Novartis Animal Health signed an agreement March 31 with Australian pharmaceutical company Phosphagenics Ltd. to develop a transdermal insulin delivery system for pets.
The formulation and potential product is still in the planning stages. But a Phosphagenics spokesperson touted the potential benefits of trandermal-applied insulin: more user-friendly than injections, improving client compliance and the use of insulin for companion animals.
Novartis will pay to develop the product and compensate Phosphagenics with additional royalties and milestone payments if the product is released in the market.